XBiotech Achieves Milestone for Production of its New Potential Blockbuster Anti-IL-1? Therapy
XBiotech Inc. (XBIT)
Last xbiotech inc. earnings: 8/9 03:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
xbiotech.com/about/investors.html
Company Research
Source: GlobeNewswire
AUSTIN, Texas, July 22, 2020 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) announced today it has achieved a crucial milestone in the development of its next generation inflammation-fighting True Human antibodies. The Company is developing a new antibody to replace a previous generation True Human anti-IL-1? antibody that was sold in 2019 for $750 million in cash and up to $600 million in milestone payments. Under terms of the sale, XBiotech was permitted to pursue discovery of new True Human anti-IL-1? antibodies for use in all areas of medicine with the exception of dermatology. XBiotech’s scientists first discovered and characterized a panel of new anti-IL-1? antibodies from a human donor earlier this year. The team has worked diligently through the COVID-19 crisis to clone the genes for the antibodies into cells that can be used for production of these novel therapeutics. The antibody products will be used in human clinical trials and ultimately commercialized. The Research
Show less
Read more
Impact Snapshot
Event Time:
XBIT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
XBIT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
XBIT alerts
High impacting XBiotech Inc. news events
Weekly update
A roundup of the hottest topics
XBIT
News
- XBiotech Inc.'s (NASDAQ:XBIT) top owners are retail investors with 44% stake, while 44% is held by insiders [Yahoo! Finance]Yahoo! Finance
- XBiotech Inc. (NASDAQ: XBIT) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- XBiotech Inc. (NASDAQ: XBIT) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- XBiotech Inc. (NASDAQ: XBIT) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- XBiotech Inc. (NASDAQ: XBIT) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
XBIT
Sec Filings
- 3/15/24 - Form 10-K
- 2/7/24 - Form SC
- 2/7/24 - Form SC
- XBIT's page on the SEC website